



CEO & INVESTOR CONFERENCE

February 8-9, 2016 • The Waldorf Astoria New York

bio.org/CEO • #BIOCE016



CEO & INVESTOR CONFERENCE

February 8-9, 2016 • The Waldorf Astoria New York

Now in its 18th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

WHY ATTEND?

- ▶ **EXPERIENCE** the largest, unbiased forum where institutional investors, industry analysts, and senior biotechnology executives shape the future investment landscape of the industry.
- ▶ **HEAR** Washington's perspective on timely developments affecting the industry.
- ▶ **EVALUATE** fresh investment opportunities including compatible, complementary and competitive companies.
- ▶ **LEARN** about the hottest clinical developments and industry catalysts by attending the conference's therapeutic workshops and business roundtables.
- ▶ **ATTEND** fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry's leading companies are headed in 2015.
- ▶ **GAIN ACCESS** to BIO's 1x1 Partnering System™ for scouting potential investments and deal partners, optimizing your time at the event.
- ▶ **HEAR** presentations from more than 150 established public and private biotech companies and non-profit funding organizations, including many you won't hear from at other investor conferences.
- ▶ **GET THE PULSE** of the current and proposed investment trends in biotechnology.
- ▶ **NETWORK** with peers, investors, and potential partners attending the conference and our exclusive receptions.

2016 Fireside Chat Speakers

Fireside Chats feature candid discussions between biopharma executives, Wall Street analysts, and other high-level industry experts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry's leading companies are headed in 2016.



Samuel D. Isaly
*Managing Partner,
OrbiMed Advisors*



John F. Milligan, PhD
*President and Chief
Operating Officer,
Gilead Sciences*



George A. Scangos, PhD
*Chief Executive Officer,
Biogen*



Dale Schenk, PhD
*President and Chief
Executive Officer,
Prothena*



Christi Shaw
*US Country Head,
President of Novartis
Corporation & President of
Novartis Pharmaceuticals
Corporation*

M&A IN OVERDRIVE: DEAL-MAKING AND MERGER INTEGRATION SUCCESS FACTORS

- **Monday, February 8, 2016**
- 5:00 PM - 5:55 PM
- JADE

As 2015 has set new records for M&A deal activity, voices in the industry are predicting 2016 to be even more active, in spite of political debates that suggest imposing restrictions. The biopharma industry has deep experience with the processes and results of M&A. Veterans of past deal cycles will share their experiences on the factors that set successful deals apart from those that disappoint investors and what lessons executives might consider before they make their next deal.

MODERATOR:

Stephen B. Thau, *Partner, Morrison & Foerster LLP*

PANELISTS:

Carol Gallagher, PharmD
Partner, New Enterprise Associates

Henry Gosebruch
*Executive Vice President and Chief
Strategy Officer, AbbVie Inc.*

James Sapirstein, RPh
*Chief Executive Officer, ContraVir
Pharmaceuticals*

Mark Timney
*Chief Executive Officer, Purdue
Pharma L.P.*

REGULATORY POLICY OUTLOOK: PDUFA VI AND YOU

- **Tuesday, February 9, 2016**
- 8:00 AM - 8:55 AM
- JADE

The major negotiations of the next FDA prescription drug user fee act will take place in 2016 with the role of biomarkers, timelines, and patient-reported outcomes as just a few of the dimensions under review. BIO policy experts, investors, and CEOs close to the approvals process will explain the opportunities and risks, plus where the audience can get involved.

MODERATOR:

Cartier Esham, PhD, *Executive Vice President, Emerging Companies, BIO*

PANELISTS:

Elizabeth Krutoholow
Analyst, Bloomberg Intelligence

Jonathan Leff
*Partner, Deerfield Management;
Chairman, Deerfield Institute*

Richard F. Pops
*Chairman & Chief Executive Officer,
Alkermes*

Panel and speaker updates at bio.org/ceo

February 8-9, 2016 • The Waldorf Astoria New York

UNDERSTANDING THE TOTAL VALUE OF INNOVATIVE THERAPIES

► **Tuesday, February 9, 2016**

► 10:30 AM - 11:45 AM

► **JADE**

The medical advances of the past couple of years, plus the promising cures and therapies in final stages of development, have sparked a public debate about the economic role of drugs and therapies within the broader picture of health care spending. As scientific progress is pushing against traditional economic expectations and relationships, this panel will assemble a diversity of perspectives to discuss how to ensure the broadest benefits for patients long-term through the investor/biopharma/payer/provider ecosystem.

MODERATOR:

Margaret Anderson, *Executive Director, FasterCures*

PANELISTS:

Ron Cohen, MD
President and Chief Executive Officer, Acorda Therapeutics

Scott Gottlieb, MD
Resident Fellow, American Enterprise Institute

Matthew Herper
Forbes

Ed Silverman
Pharmalot, STATnews.com

DIGITAL HEALTH SPOTLIGHT: BUILDING CONTINUOUS RELATIONSHIPS WITH PATIENTS

► **Tuesday, February 9, 2016**

► 3:00 PM - 3:55 PM

► **JADE**

More than \$4B in venture funding this year has gone into digital health, with significant biopharma corporate venture investment in tools for patient engagement. Why? And what are the implications for biotech drug development? Investors, entrepreneurs, and biopharma supporters will explain their visions of digital health care that involve an ongoing data dialogue with patients.

PANELISTS:

Jared Bauer
Chief Executive Officer, ApolloDx

Jeffrey Brewer
President & Chief Executive Officer, Bigfoot Biomedical

Aaron Nelson, MD, PhD
General Partner, dRx Capital; Strategic Project Leader, Trials of the Future, Novartis Pharmaceuticals

Anand Sanwal
Founder and Chief Executive Officer, CB Insights

François Teboul, MD
Medical Director and Research & Development Manager, Visiomed Group SA

MARKET OUTLOOK: POST-PEAK ADJUSTMENTS BEING MADE BY PUBLIC, PRIVATE, AND CROSSOVER INVESTORS

- ▶ **Tuesday, February 9, 2016**
- ▶ 4:30 PM - 5:25 PM
- ▶ **ASTOR**

With 2015 market indices at near break-even for the year, after a stellar 2014, investors and IPO-candidates are re-evaluating their plans, even as new breakthrough therapies are reaching patients faster than ever before and digital health grows in impact. This panel of industry experts will share their views on which subsectors of biopharma will prosper most and which will face headwinds across 2016, likely to be a raucous election year, with implications for the industry.

MODERATOR:

Robert A. Freedman, *Partner, Fenwick & West LLP*

PANELISTS:

John Chambers

*Vice-Chairman and Head of
Healthcare Investment Banking,
ROTH Capital Partners*

Asthika Goonewardene

*Biotechnology Analyst,
Bloomberg Intelligence*

Brian Hagerty

*Senior Director, New York
Stock Exchange*

Bong Koh

Partner, Venrock

Rajeev Shah

*Managing Director & Portfolio
Manager, RA Capital*

February 8-9, 2016 • The Waldorf Astoria New York

IMPROVING ONCOLOGY CLINICAL TRIALS: LESSONS FROM ALTERNATIVE TRIAL DESIGNS SUCH AS LUNG- MAP AND NCI-MATCH

► **Monday, February 8, 2016**

► 8:00 AM - 8:55 AM

► **JADE**

The National Cancer Institute and others have launched clinical trials with innovative basket, umbrella, and uncommon designs to fight the accelerating costs of testing therapies and to clarify which drugs work best against specific tumor types. Major biopharmas are collaborating as never before to understand how to identify which new therapeutic approaches and combination therapies can best fight and cure cancers. This panel will review Lung-MAP, NCI-MATCH, and news on the latest progressive approaches.

MODERATOR:

Ellen V. Sigal, PhD, Chairperson and Founder, Friends of Cancer Research

PANELISTS:

Paul Biondi

Senior Vice President, Head of
Business Development, Bristol-
Myers Squibb

Andreas Dreps, PhD

Senior Vice President and Global
Head Drug Development Unit,
ICON plc

Eric Rowinsky, MD

Executive Chairman, President, Head
of Clinical Advisory Board, Rgenix

Joseph Sparano, MD

Albert Einstein College of Medicine;
NCI-Match trial

ADVANCES IN OPHTHALMOLOGY: THERAPIES FOR SAVING SIGHT

► **Monday, February 8, 2016**

► 9:30 AM - 10:25 AM

► **JADE**

Widespread adoption by providers and patients of recent FDA approvals in this therapeutic area has helped increase support for new clinical approaches, accelerate venture investment, and support activity in ophthalmology licensing deals. In particular, gene therapy approaches and the ability to conduct trials more quickly versus other therapeutic areas have produced multiple dimensions of treatments that were unimagined earlier this decade. Hear from companies working to apply these discoveries to soon provide assistance in preserving vision for patients.

MODERATOR:

Tony Gibney, Managing Director, Leerink Partners LLC

PANELISTS:

Guy S. Eakin, PhD

Vice President, Scientific Affairs,
BrightFocus Foundation

David R. Guyer, MD

Chairman, Co-Founder
and Chief Executive Officer,
Ophtotech

Nouhad Hussein

Vice President, Business
Development, Regeneron

David P. Southwell

President and Chief Executive
Officer, Inotek Pharmaceuticals

THERAPEUTIC SESSIONS

ADDRESSING ALZHEIMER'S DISEASE: NEW DIRECTIONS AND SIGNS OF PROGRESS?

► **Monday, February 8, 2016**

► 4:00 PM - 4:55 PM

► **JADE**

More than 5 million people in the U.S. have Alzheimer's today, with 40% growth in the patient population expected across the next decade, and limited treatment options. After numerous disappointing clinical trials, new approaches to attacking the disease are finding positive scientific results and growth in investment levels. Hear from clinical researchers, biotech CEOs, and patient advocacy group representation to explain how the field is pivoting from the failures of recent approaches to make use of new generation findings, innovative in vitro techniques, and alternative therapeutic angles.

MODERATOR:

Sue Peschin, *President & Chief Executive Officer, Alliance for Aging Research*

PANELISTS:

Andrew Fein
*Managing Director,
Senior Healthcare Analyst,
H.C. Wainwright & Co., LLC*

Sharon Mates, PhD
*Chief Executive Officer,
Intra-Cellular Therapies*

Mark Schoenebaum, MD
*Senior Managing Director, Head of
Health Care Research Team,
Evercore ISI*

Martin Tolar, MD, PhD
*Founder, President & Chief
Executive Officer, Alzheon*

CRISPR/CAS9: EXCITEMENT AND CONCERN FOR FIRST THERAPIES

► **Tuesday, February 9, 2016**

► 1:00 PM - 1:55 PM

► **JADE**

In the past three years, the speed and flexibility of manipulating DNA via CRISPR/Cas9 techniques has led to a profusion of research discoveries and hundreds of millions of dollars in financial investments. Original applications plus methods for accelerating existing gene therapy plans are moving CRISPR-related projects closer to human therapeutic trials. Where will this technique likely first demonstrate therapeutic value? What remaining questions about CRISPR's reliability and limitations must be answered before commercialization?

MODERATOR:

Michael King
Managing Director & Senior Biotech Analyst, JMP Securities

PANELISTS:

Katrine Bosley
*Chief Executive Officer,
Editas Medicine*

André Choulika, PhD
*Chairman and Chief Executive
Officer, Cellectis*

Sapna Srivastava, PhD
*Chief Financial Officer and
Chief Scientific Officer, Intellia
Therapeutics*

February 8-9, 2016 • The Waldorf Astoria New York

The 2016 BIO CEO & Investor Conference will better accommodate the growing diversity of investors and companies. While the majority of presenting companies at this event are publicly traded, with about half trading with market capitalizations above \$100M, this meeting will once again feature a unique track of more than 30 high-caliber and established private company presentations.

Public Companies

Abeona Therapeutics, Inc.
AcelRx Pharmaceuticals
Actinium Pharmaceuticals, Inc.
Adaptimmune Therapeutics plc
Addex Therapeutics Ltd
Aethlon Medical, Inc.
Aimmune Therapeutics
Akari Therapeutics Plc
Akebia Therapeutics
Alcobra
Alkermes
Alnylam Pharmaceuticals
Anavex Life Sciences Corp.
Apricus Biosciences, Inc.
Aradigm Corporation
ARCA biopharma, Inc.
Argos Therapeutics, Inc.
Ascendis Pharma A/S
Asterias
Athersys, Inc.
Aurinia Pharmaceuticals Inc
AVEO Oncology
BioBlast Pharma Ltd.
Biocept, Inc.
BioLife Solutions, Inc.
BioLineRx
BiondVax Pharmaceuticals Ltd.
Bionik Laboratories
Bionomics Ltd
Bio-Path Holdings, Inc.
BioSpecifics Technologies Corp.
Biotie Therapies Corp
BioTime
Caladrius Biosciences, Inc.
Calithera Biosciences
Can-Fite BioPharma, Ltd.
Capricor
Catalyst Biosciences, Inc.
Catalyst Pharmaceuticals
Celator Pharmaceuticals, Inc
Cellestis
CEL-SCI Corporation
Cerecor Inc.
Cerulean Pharma Inc.
Cesca Therapeutics Inc.
CoLucid Pharmaceuticals, Inc.

Conatus Pharmaceuticals Inc.
ContraFect Corporation
ContraVir Pharmaceuticals, Inc.
Corbus Pharmaceuticals Holdings, Inc.
Curis, Inc.
Cyclacel Pharmaceuticals, Inc.
CymaBay Therapeutics, Inc.
Cytokinetics, Inc
CytRx Corporation
Delcath Systems, Inc.
DelMar Pharmaceuticals, Inc.
Diffusion Pharmaceuticals Inc.
Dipexium Pharmaceuticals, Inc.
DURECT Corporation
Emisphere Technologies, Inc.
ERYTECH Pharma
Foamix Pharmaceuticals Ltd.
Galectin Therapeutics Inc
Galena Biopharma Inc.
Genocea Biosciences Inc
GenVec, Inc.
GlycoMimetics
Histogenics Corporation
Horizon Pharma plc
ImmunoCellular Therapeutics, Ltd
Imugene Ltd
La Jolla Pharmaceutical Company
MabVax Therapeutics Holdings, Inc.
Mast Therapeutics, Inc.
Matinas BioPharma Holdings, Inc.
MEI Pharma, Inc.
Mirna Therapeutics Inc.
Navidea Biopharmaceuticals, Inc.
Nemus Bioscience, Inc.
Neos Therapeutics
Neovacs
NephroGenex, Inc.
Nestlé Health Science
Newron Pharmaceuticals SpA
Nicox
Northwest Biotherapeutics, Inc.
Oasmia Pharmaceutical AB
Ocera Therapeutics, Inc
OncBioMune Pharmaceuticals INC
OncoCyte
Oncolytics Biotech
OncoMed Pharmaceuticals, Inc.
Onconova Therapeutics, Inc.

OncoSec Medical Incorporated
Opexa Therapeutics
Oramed Pharmaceuticals
Orexigen Therapeutics, Inc.
Oxigene, Inc.
PAION Inc.
Palatin Technologies, Inc.
PDL BioPharma, Inc.
Pieris Pharmaceutical
Pluristem Therapeutics Inc.
Probiobdrug AG
Progenics Pharmaceuticals, Inc.
ProMetic Life Sciences
Proton Therapeutics, Inc.
Prothena Corporation plc
Provectus Biopharmaceuticals, Inc
pSivida Corp.
PuriCore
RedHill Biopharma Ltd
Relypsa, Inc.
RespireRx
Resverlogix Corp.
Rexahn Pharmaceuticals
RXi Pharmaceuticals Corporation
SciClone Pharmaceuticals Inc
Selvita S.A.
Sophiris
SteadyMed Therapeutics
StemCells, Inc.
Stemline Therapeutics
Summit Therapeutics
Synthetic Biologics, Inc.
TG Therapeutics, Inc.
TiGenix NV
Tobira Therapeutics, Inc
Tonix Pharmaceuticals Holdings, Inc.
Trevena Inc
Vascular Biogenics
VBI Vaccines Inc.
Verastem, Inc.
vTv Therapeutics
Xtant Medical Holdings, Inc
Zafgen
ZIOPHARM Oncology, Inc.

Private Companies
Accera Inc
AgeneBio, Inc.

Albireo Ltd.
Altimune, Inc.
Aridis Pharmaceuticals Inc.
ArmaGen, Inc.
Atreca, Inc.
Aurora BioPharma, Inc.
Azevan Pharmaceuticals, Inc.
Batavia N.V.
Bell Biosystems, Inc.
Bigfoot Biomedical
Biothera Pharmaceutical Inc.
CaroGen Corporation
Complexa Inc
EnGeneC Ltd.
G1 Therapeutics Inc.
GNS Healthcare, Inc.
GrayBug, Inc
Grupo Biotoscana SL
Helomics Corporation
Highland Therapeutics Inc.
Izun Pharmaceuticals
Kadmon
KineMed, Inc
KPI Therapeutics
Mariposa Health Inc
Milestone Pharmaceuticals Inc.
Millendo Therapeutics Inc.
Minerva Biotechnologies Corporation
Nimbus Therapeutics LLC
Ocugen, Inc.
Opsona Therapeutics Ltd
OticPharma, Ltd.
Progenra Inc
Rebiotix Inc
Sutro Biopharma
Symic Biomedical, Inc.
Synlogic
Targazyme, Inc.
Tyrogenex, Inc.
Xcovery, Holding Company
Ziarco Group Ltd

Patient Advocacy Groups

Hereditary Neuropathy Foundation
JDRF
Leukemia & Lymphoma Society
Michael J. Fox Foundation
NY Stem Cell Foundation

*List accurate as of 1/11/16

2016 PARTICIPATING INVESTORS*

Investors

Adamas Healthcare Fund
Advent Capital Management
American Century Investments
Anson Group Canada
Archer Avenue Partners
Arcus Ventures
Asahi Kasei America
Ashford Capital Management
Aspire Capital
ATEL Ventures
ATEM Capital
Athyrium Capital Management
BDC Capital Healthcare Fund
Biomed Ventures
Brookside Capital/Bain Capital
Burrage Capital
Calamos Investments
Caxton Associates LP
Cedrus Investments
Daniloff Capital
Deerfield Management
Easton Capital
EcoR1
EGB Advisors
Enso Ventures
Federated Kaufman Fund
Five Corners Capital
Foresite Capital Management
Fountain Healthcare Partners
H.I.G. Bioventures
Hercules Technology Growth Capital
Jump Capital
Juvenile Diabetes Research Foundation
Knoll Capital Management
Kodiak Capital Group
Lincoln Park Capital
Longitude Capital
Magna
Marathon Asset Management
Merlin Nexus
Mount Sinai Fund
MPM Capital/Science Seed
Muse Capital
New Enterprise Associates
NJ Investment Division
NYS Innovation VC Fund
Oxford Finance
Pappas Ventures
Pipeline Capital
Point 72 Partners
QVT

Investor Registration Up
MORE THAN 30% over 2015.

RA Capital
Ridgeback Capital Management
Sabby Management
Sarissa Capital Management
Seaview LLC
Sector Asset Management
Slater Technology Fund
Sofinnova Ventures
Special Situations Life Sciences Fund
Symphony Capital
Temasek
The Lind Partners
V2M Capital
Venrock
Versant Ventures
Weiss Multi Strategy Advisers
Wexford Capital

Research Analysts

Bank of America/Merrill Lynch
Barclays
Brean Capital
Cantor Fitzgerald
Chardan Capital Markets
Cowen
FBR & Co.
Griffin Securities
H.C. Wainwright
JMP
Ladenburg Thalmann
Laidlaw & Company
Leerink
Lifetech Capital
Maxim Group
Morgan Stanley
Needham & Co.
Noble Life Sciences
Piper Jaffray
RBC Capital Markets
ROTH Capital Partners
Stifel
Source Capital
Sun Trust Humphrey Robinson
WallachBeth

*List accurate as of 1/13/16


February 8-9, 2016 • The Waldorf Astoria New York



Using the system, companies are able to:

- ▶ Pre-schedule 30-minute private 1x1 meetings
- ▶ Source potential collaborations and funding opportunities with an international audience
- ▶ Communicate directly with prospective investors and C-level executives in biotech and pharma
- ▶ Search company and investor profiles for potential business partnerships

Audience Demographics




Attendees: **1,400+**

One-on-One Meetings: **2,200+**


Registered Investors: **650**

Company Presentations: **170**

Breakdown by Market Cap:



Breakdown by Therapeutic Focus:



SPONSORS

Local Co-Host



Supporting Bank Sponsors



LAZARD



Double Helix Sponsor

abbvie

Helix Sponsors



Conference Sponsors



Media Partners



Regional Partners



February 8-9, 2016 • The Waldorf Astoria New York



Katrine Bosley

*Chief Executive Officer,
Editas Medicine*



John Chambers

*Vice-Chairman and Head of
Healthcare Investment Banking,
ROTH Capital Partners*



Carol Gallagher

*Partner, New Enterprise
Associates*



Jeff Hatfield

*Chief Executive Officer, Vitae
Pharmaceuticals*



Nouhad Hussein

*Vice President, Business
Development, Regeneron*



Mike King

*Managing Director & Senior
Biotech Analyst, JMP Securities*



Bong Koh

Partner, Venrock



Jonathan Leff

*Partner, Deerfield
Management*



Michael Mirsky

*Managing Director,
Investment Banking,
H.C. Wainwright & Co., LLC*



Oleg Nodelman

*Founder & Managing
Director, EcoR1 Capital*



Rajeev Shah

*Managing Director & Portfolio
Manager, RA Capital*



Nathan Tinker

President, New York BIO

RESERVE YOUR SPOT TODAY!



BIO offers a number of ways for conference attendees to save money on their registration fees.



Discounted packages for presenting companies and organizations bringing three or more attendees.



Special rates for academics, non-profits, government, service providers and suppliers.

Complimentary registration is available to qualified investors*.

*Defined as institutional, private equity, angel and venture investors with funds on-hand, whose primary activity is direct investment in research and development companies (e.g., hedge fund, mutual fund, or venture fund). Equity research analysts from investment banking institutions and buy-side analysts also qualify as investors.

The fund name, portfolio type, or other helpful information is needed for BIO to process your registration appropriately. Receipt of complimentary registration for a prior year's event does not automatically qualify a registrant for complimentary registration in 2016.

Go to bio.org/bioceo/register and register now!

Registration Fees

	BIO Member Rate	Standard Rate
Biotech/Pharma Company	\$2,000	\$2,500
Group Package ¹	\$5,400	\$6,750
Academic/Gov't/Non-Profit ³	\$875	\$875
Service Providers/Suppliers	\$4,000	\$5,000

¹All eligible biotech and pharma companies receive up to a 10% discount when registering three employees. If your company is registering more than three employees, please contact BIO for further discounts. Please note: The group package rate does NOT include a corporate presentation.

²A code is required to register as a presenter for a company presentation. If you have already been confirmed as a presenter, you should have received a registration code with a checklist. If you are interested in presenting, please contact Brian Pinkston at bpinkston@bio.org.

³A code is required for academic, government, and non-profit registration. Please send your request to BD_Registration@bio.org.

Presentation Fees

	BIO Member Rate	Standard Rate
Public Company ^{1/2}	\$3,000	\$3,750
Private Company ^{1/2}	\$2,000	\$2,500

Hotel Venue

The Waldorf Astoria New York
301 Park Avenue
New York, NY 10022

A limited number of rooms are available at the Waldorf Astoria. Please make your reservations, directly with the hotel, as soon as possible to secure your room at the discounted rate.

JOIN THE CONVERSATION:

Learn more about Biotechnology at bio.org

Engage with the Biotech Community at BIOtech-NOW.org

Follow us on Twitter [@bio1x1](https://twitter.com/bio1x1) or [#BIOCEO16](https://twitter.com/BIOCEO16)

Become a fan on Facebook (facebook.com/IAmBiotech)



bio.org/CEO • [#BIOCEO16](https://twitter.com/BIOCEO16)